Cargando…

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML

The development of leukemia is a step-wise process that is associated with molecular diversification and clonal selection of neoplastic stem cells. Depending on the number and combinations of lesions, one or more sub-clones expand/s after a variable latency period. Initial stages may develop early i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valent, Peter, Kern, Wolfgang, Hoermann, Gregor, Milosevic Feenstra, Jelena D., Sotlar, Karl, Pfeilstöcker, Michael, Germing, Ulrich, Sperr, Wolfgang R., Reiter, Andreas, Wolf, Dominik, Arock, Michel, Haferlach, Torsten, Horny, Hans-Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387423/ https://www.ncbi.nlm.nih.gov/pubmed/30759825 http://dx.doi.org/10.3390/ijms20030789

Ejemplares similares

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology
por: Hoermann, Gregor, et al.
Publicado: (2020)

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
por: Cappelli, Luca Vincenzo, et al.
Publicado: (2021)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts
por: Valent, Peter, et al.
Publicado: (2018)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal()
por: Valent, Peter, et al.
Publicado: (2017)

Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes
por: Valent, Peter, et al.
Publicado: (2022)

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
por: Huber, Sandra, et al.
Publicado: (2023)

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
por: Peter, Barbara, et al.
Publicado: (2017)

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase
por: Huber, Sandra, et al.
Publicado: (2022)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

AML classification in the year 2023: How to avoid a Babylonian confusion of languages
por: Huber, Sandra, et al.
Publicado: (2023)

The underestimated role of basophils in Ph(+) chronic myeloid leukaemia
por: Valent, Peter, et al.
Publicado: (2018)

P689: CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?
por: Haferlach, Claudia, et al.
Publicado: (2023)

Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease
por: Hoermann, Gregor
Publicado: (2022)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis—Masters of Survival and Clonality?
por: Pleyer, Lisa, et al.
Publicado: (2016)

P1402: ALTERATIONS OF HUMAN BONE MARROW NICHE IN CLONAL HEMATOPOIESIS AND AML
por: Dragieva, Y., et al.
Publicado: (2022)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
por: Herrmann, Harald, et al.
Publicado: (2012)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity
por: Valent, Peter, et al.
Publicado: (2021)

Chipping in on clonal hematopoiesis
por: Gillis, Nancy K., et al.
Publicado: (2017)

Evolution of clonal hematopoiesis
por: van Zeventer, Isabelle A., et al.
Publicado: (2023)

Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML
por: Heini, Alexander D., et al.
Publicado: (2021)

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2019)

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations
por: Höllein, Alexander, et al.
Publicado: (2019)

The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm
por: Jawhar, Mohamad, et al.
Publicado: (2017)

Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations?
por: Cypris, Olivia, et al.
Publicado: (2019)

Clonal Hematopoiesis and Vascular Disease
por: Amancherla, Kaushik, et al.
Publicado: (2022)

Discovering the drivers of clonal hematopoiesis
por: Pich, Oriol, et al.
Publicado: (2022)

Genetic Predisposition to Clonal Hematopoiesis
por: Quiros, Pedro M., et al.
Publicado: (2023)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

ICON: Eosinophil Disorders
por: Valent, Peter, et al.
Publicado: (2012)

Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts
por: Valent, Peter, et al.
Publicado: (2020)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_64ivik7dr8qruuu6rn5ftum1r7